Evidence map›Paper›PMID 25592743›Full record

ArticleArthritis research & therapy2015

Overexpression of cystatin C in synovium does not reduce synovitis or cartilage degradation in established osteoarthritis.

Sirkka Kyostio-Moore, Susan Piraino, Patricia Berthelette, Nance Moran, Joseph Serriello, Alison Bendele, Cathleen Sookdeo, Bindu Nambiar, Patty Ewing, Donna Armentano and 1 more

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Sirkka Kyostio-MooreGene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. sirkka.kyostio-moore@genzyme.com.
Susan PirainoGene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. susan.piraino@genzyme.com.
Patricia BertheletteGene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. patricia.berthelette@genzyme.com.
Nance MoranOrthopaedic Research, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. nance.moran@genzyme.com.
Joseph SerrielloOrthopaedic Research, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. joseph.serriello@genzyme.com.
Alison BendeleBolder BioPATH, 5541 Central Avenue, Boulder, CO, USA. Alison@bolderbiopath.com.
Cathleen SookdeoGene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. Cathleen.sookdeo@genzyme.com.
Bindu NambiarGene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. Bindu.nambiar@genzyme.com.
Patty EwingPathology, Genzyme, a Sanofi Company, 5 Mountain Road, Framingham, MA, USA. lessleyb@aol.com.
Donna ArmentanoGene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. Donna.armentano@genzyme.com.
Gloria L MatthewsOrthopaedic Research, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA. Gloria.matthews@genzyme.com.
Genesys (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCathepsin K (catK) expression is increased in cartilage, bone and synovium during osteoarthritis (OA). To study the role of catK expression and elevated cathepsin activity in the synovium on cartilage destruction in established OA, we overexpressed cystatin C (cysC), a natural cysteine protease inhibitor, in the synovium of rabbit OA joints.

methodsThe ability of cysC to inhibit activity of cathepsins in rabbit OA synovium lysates was tested in vitro using protease activity assay. In vivo, the tissue localization of recombinant adeno-associated virus (rAAV) with LacZ gene after intra-articular injection was determined by β-galactosidase staining of rabbit joints 4 weeks later. To inhibit cathepsin activity in the synovium, a rAAV2-encoding cysC was delivered intra-articularly into rabbit joints 4 weeks after OA was induced by anterior cruciate ligament transection (ACLT). Seven weeks postinjection, endogenous catK and cysC levels as well as the vector-derived cysC expression in the synovium of normal and OA joints were examined by RNA quantification. Synovial cathepsin activity and catK, catB and catL protein levels were determined by activity and Western blot analyses, respectively. Synovitis and cartilage degradation were evaluated by histopathological scoring.

resultsIn vitro, the ability of cysC to efficiently inhibit activity of purified catK and OA-induced cathepsins in rabbit synovial lysates was demonstrated. In vivo, the intra-articular delivery of rAAV2/LacZ showed transduction of mostly synovium. Induction of OA in rabbit joints resulted in fourfold increase in catK mRNA compared to sham controls while no change was detected in endogenous cysC mRNA levels in the synovium. Protein levels for catK, catB and catL were also increased in the synovium with a concomitant fourfold increase in cathepsin activity. Joints treated with rAAV2/cysC showed both detection of vector genomes and vector-derived cysC transcripts in the synovium. Production of functional cysC by the vector was demonstrated by complete block of cathepsin activity in the synovium. However, this did not decrease synovitis, bone sclerosis or progression of cartilage degradation.

conclusionsIncreased production of natural cathepsin inhibitor, cysC, in OA synovium does not alleviate synovitis or cartilage pathology during a preexisting OA.

Indexed as

AnimalsCartilage, ArticularCystatin CGene Expression RegulationHumansMaleOsteoarthritisRabbitsSynovial MembraneSynovitisCystatin C

Identifiers

PMID25592743
PMCPMC4350912
OpenAlexW2155503585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.